PMID: 11605992Oct 19, 2001Paper

Limitation of infarct size and attenuation of myeloperoxidase activity by an endothelin A receptor antagonist following ischaemia and reperfusion

Basic Research in Cardiology
A T GononJ Pernow

Abstract

It has previously been shown that endothelin (ET) receptor antagonists limit myocardial ischaemia/reperfusion (I/R) injury. The mechanism behind this effect is still unclear. The aim of this study was to elucidate the possible relationship between cardioprotection by an ET(A) receptor antagonist and inhibition of neutrophil accumulation or activation in the myocardium determined as myeloperoxidase (MPO) activity during I/R. Anaesthetised pigs were subjected to 45 min ischaemia by ligation of the left anterior descending coronary artery (LAD) followed by 4 h of reperfusion. Infiltration of MPO-containing cells, presumably neutrophils, into the ischaemic area was confirmed with an immunohistochemical technique using antibodies against porcine MPO. Vehicle (n = 7) or the selective ET(A) receptor antagonist LU 135252 (LU; n = 7) were given into the LAD during the last 10 min of ischaemia and the first 5 min of reperfusion. There were no significant differences in LAD flow, mean arterial pressure, heart rate, or rate pressure product between the groups during I/R. The area at risk was similar in the two groups. LU reduced the final infarct size to 40+/-6% of the area at risk compared to 80+/-6% in the vehicle group (P < 0.001). Endo...Continue Reading

Citations

Mar 31, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Rosanna Di Paola, Salvatore Cuzzocrea
Nov 22, 2011·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Bernhard RichterHeinz D Gössinger
Apr 6, 2004·Current Opinion in Pharmacology·George V MoukarbelAntoine B Abchee
Oct 17, 2002·Nitric Oxide : Biology and Chemistry·Andrey V GourinePer-Ove Sjöquist
Jun 19, 2012·Canadian Journal of Physiology and Pharmacology·Ting-Ting LiJun Peng
Feb 16, 2010·Biochemical and Biophysical Research Communications·Zi YanHui-Rong Liu
Apr 29, 2015·International Heart Journal·Shih-Tai ChangJu-Feng Hsiao
Apr 10, 2012·Life Sciences·John PernowFelix Böhm
May 13, 2015·Seminars in Nephrology·Matthias Barton, Andrey Sorokin
Oct 8, 2014·Archivum Immunologiae Et Therapiae Experimentalis·Agata KowalczykAnna Goraca
Jul 6, 2014·Journal of Cardiovascular Pharmacology and Therapeutics·Sudhakar SatturGregg W Stone
Sep 15, 2011·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·Z Y WangX Lu
Aug 13, 2011·Arteriosclerosis, Thrombosis, and Vascular Biology·Laurent BarandonCécile Duplàa
Dec 25, 2003·American Journal of Physiology. Heart and Circulatory Physiology·Adrian T GononJohn Pernow
Dec 19, 2019·Antioxidants & Redox Signaling·Chrishan J A RamachandraDerek J Hausenloy
Jul 4, 2003·Canadian Journal of Physiology and Pharmacology·Peter CernacekJean-Lucien Rouleau

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.